Figure 4.

Immune checkpoint therapy is less effective in AB12 and Line-1M.

Tumour bearing BALB/c mice were treated with antibodies targeting selective immune checkpoint molecules either alone, or in combination when tumours were 25 mm² to 30 mm² (treatment days indicated by up ticks). Data shows survival and tumour growth plots for mice bearing AB12 (A-B) and Line-1M (D-E) tumours treated with indicated ICPB therapies. Tumour growth curves for individual mice in each group compared to PBS controls for AB12 (C) and Line-1M (F). Each line represents a tumour bearing mouse with significant differences for groups relative to PBS controls shown unless otherwise stated. Horizontal lines indicates significant delay in tumour growth over time for each group compared to PBS. Combined data from two independent experiments analysed using Log rank (Mantel-Cox) for survival curves or Mixed model ANOVA for mean tumour growth. * = p < 0.05, *** = p < 0.001, **** = p < 0.0001, ns = not significant.